香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. 百奧賽圖（北京）醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2315） 內幕消息 建議A股發行的進度 本公告由百奧賽圖（北京）醫藥科技股份有限公司（「本公司」）遵照香港聯合交易所 有限公司證券上市規則（「上市規則」）第13.09(2)(a)條及證券及期貨條例（香港法 例第571章）第XIVA部的內幕消息條文（定義見上市規則）而發出。 茲提述本公司日期為2023年3月6日、2023年3月15日及2023年6月20日的公告及 日期為2023年3月31日的通函，當中載有（其中包括）建議首次公開發行A股（「建 議A股發行」）並在上海證券交易所（「上交所」）科創板上市的相關事宜。 本公司已就建議A股發行提交了《首次公開發行股票並在科創板上市招股章程（上 會稿）》（「招股章程上會稿」），全 ...

Group 1 - The Shanghai Stock Exchange's Listing Review Committee will hold its 38th meeting on September 24, 2025, to review the initial public offering (IPO) of Bai'ao Saitou (Beijing) Pharmaceutical Technology Co., Ltd. [1] - Bai'ao Saitou plans to list on the Sci-Tech Innovation Board and aims to raise 1.18504 billion yuan, which will be used for the construction of a drug early research and development service platform, antibody drug research and evaluation projects, preclinical research projects, and to supplement working capital [1] - As of the signing date of the prospectus, Shen Yuele holds 6.6086% of the company's shares, while Ni Jian holds 7.2621%. Shen Yuele and Ni Jian are spouses and together control 27.0291% of the voting rights, making them the co-controlling shareholders and actual controllers of Bai'ao Saitou [1] Group 2 - The sponsor (lead underwriter) for Bai'ao Saitou is China International Capital Corporation, with representatives Qi Yao and Zhang Weixian [2]

Core Viewpoint - 百奥赛图-B has signed a licensing agreement with German ADC developer Tubulis to utilize its RenMice fully human antibody development platform for innovative ADC therapies, indicating strong international competitiveness and drug conversion potential [1] Group 1: Company Developments - 百奥赛图-B's stock rose over 7% in the afternoon trading session, with a current price of 26.58 HKD and a trading volume of 16.7354 million HKD [1] - The agreement with Tubulis includes an upfront payment, milestone payments for development, regulatory, and commercialization, as well as a single-digit percentage of net sales [1] - On September 4, 百奥赛图-B signed an antibody option and evaluation agreement with Merck to assess antibodies developed using the RenMice platform for advanced solutions like nucleic acid drug delivery [1] Group 2: Market Implications - The agreements with Tubulis and Merck highlight the international competitiveness of 百奥赛图-B's fully human antibody platform and its potential for drug conversion [1]

Core Viewpoint - The company BaiO Saite-B (02135) has signed a licensing agreement with German ADC developer Tubulis, leveraging its RenMice fully human antibody development platform for innovative ADC therapies, which is expected to enhance its market position and revenue potential [1] Group 1: Licensing Agreement with Tubulis - On September 16, BaiO Saite announced a licensing agreement with Tubulis to utilize its RenMice platform for developing ADC therapies, which includes an upfront payment and milestone payments based on development, regulatory, and commercialization achievements, along with a single-digit percentage of net sales [1] - The stock price of BaiO Saite increased by over 7% in the afternoon trading session, reflecting positive market sentiment regarding the agreement [1] Group 2: Previous Agreement with Merck - On September 4, BaiO Saite signed an antibody option and evaluation agreement with Merck to assess the fully human antibodies developed using the RenMice platform for potential applications in nucleic acid drug delivery [1] - The agreements with Tubulis and Merck highlight the international competitiveness and drug conversion potential of BaiO Saite's fully human antibody platform, as stated by the company's Chairman and CEO Shen Yuelai [1]

Core Insights - The company, Baiaosaitu, has secured two significant licensing agreements within a month, highlighting the value of its proprietary RenMice fully human antibody development platform [1][2] - The company has established itself as a leader in the innovative molecular licensing space in China, with a total of 280 licensing projects, including partnerships with seven of the top ten global pharmaceutical companies [2][3] Group 1: Licensing Agreements - On September 16, Baiaosaitu signed an antibody licensing agreement with Tubulis, which will utilize Baiaosaitu's RenMice platform for developing innovative ADC therapies [1] - Just over a week prior, on September 4, Baiaosaitu entered into an antibody option and evaluation agreement with Merck to assess antibodies developed using the RenMice platform [1] - These agreements demonstrate the international competitiveness and drug conversion potential of Baiaosaitu's fully human antibody platform [1] Group 2: Financial Performance - In the first half of the year, Baiaosaitu achieved a revenue of 621 million yuan, representing a year-on-year growth of over 51% [2] - The company's gross margin remained high at approximately 74.4%, with a net profit of 48 million yuan [2] - The stock price of Baiaosaitu increased significantly, from a low of 7.8 HKD per share to a high of 28.58 HKD per share, reflecting a growth of over 320% since the beginning of the year [2] Group 3: Research and Development - Baiaosaitu's R&D expenses for the first half of the year were approximately 209 million yuan, an increase of 29.3% year-on-year [4] - The company has obtained 195 authorized patents and submitted 496 patent applications, focusing on expanding its fully human antibody library [4] - Baiaosaitu aims to enhance its core advantages in target humanized mouse and fully human antibody discovery by integrating AI and automation into its R&D processes [4]

Core Insights - The company, Baiaosaitu, has signed an antibody option and evaluation agreement with German pharmaceutical Merck to jointly develop cutting-edge solutions for nucleic acid drug delivery using antibody-conjugated lipid nanoparticles (LNP) [1] - The agreement allows Merck to evaluate Baiaosaitu's fully human antibodies developed through its proprietary RenMice platform, with Merck having the option for global exclusive rights to selected antibodies [1] - Baiaosaitu's CEO highlighted the potential of the antibody-conjugated delivery system and the broad application prospects of fully human antibodies beyond traditional therapies [1] Financial Performance - In the first half of 2025, Baiaosaitu reported a revenue of 621 million yuan, representing a year-on-year growth of 51.3%, with nearly 70% of revenue coming from overseas collaborations [1] - The company has signed a total of 280 external licensing agreements, with 80 new agreements in the first half of the year, marking a 60% increase compared to the same period last year [1] Research and Development - Baiaosaitu has maintained high R&D investment, with R&D expenses of approximately 209 million yuan in the first half of the year, an increase of 29.3% year-on-year [2] - The company employs around 400 researchers focused on the "Thousand Mice, Ten Thousand Antibodies" initiative and preclinical research [2] - As of June 30, Baiaosaitu has obtained 195 authorized patents and submitted 496 patent applications, with plans to expand its fully human antibody library [2] Company Background - Established in 2009, Baiaosaitu began with target humanized model animals and gradually entered the fully human antibody development business [2] - The company launched the "Thousand Mice, Ten Thousand Antibodies" program in 2020 to create an "antibody shelf" and develop various advanced antibody products [2] - Baiaosaitu has become a leader in China's innovative molecular licensing, leveraging its proprietary fully human antibody mouse platform, RenMice [2]

Group 1 - The Hang Seng Index rose by 0.29%, gaining 75 points to reach 26,463 points, while the Hang Seng Tech Index increased by 1.11%. The early trading volume in Hong Kong was HKD 162 billion [1] - CRO concept stocks saw significant gains, with Kanglong Chemical (03759) rising over 8% due to accelerated clinical trial review and approval processes. Other notable performers included Zhaoyan New Drug (06127) up 7%, WuXi Biologics (02269) up 5.5%, and Kelaiying (06821) up 4.2% [1] Group 2 - Yaojie Ankang (02617) surged over 33% after being included in the Hong Kong Stock Connect list, effective from September 8 [2] - The lithium battery sector performed well, with Morgan Stanley issuing a positive report on CATL, as market attention shifts to lithium demand expectations for next year. Notable stock movements included Zhongxin Hang (03931) up 4%, CATL (03750) up 7%, and Ganfeng Lithium (01772) up 4% [2] Group 3 - Yunfeng Financial (00376) increased by over 19%, with its stock price doubling within the month following the approval of its virtual asset trading services [3] Group 4 - Ruipu Lanjun (00666) rose nearly 2%, driven by sustained high production levels at major battery manufacturers and a significant increase in the company's energy storage battery shipments [4] Group 5 - Hushang Ayi (02589) gained over 8% after being included in the Hong Kong Stock Connect list, with stable growth in store numbers during the first half of the year [5] - Brainstorm Cell Therapeutics-B (06681) saw a dramatic rise, initially up 83% to a record high, and closing up 36%, with a cumulative increase of over 130% since its inclusion in the Stock Connect list on September 8. The company is noted for developing the first medical-grade digital therapy product for cognitive disorders in China [5] Group 6 - Baiao Saitu-B (02315) increased by over 11% after signing an antibody selection rights evaluation agreement with Merck to advance antibody-drug conjugate lipid delivery solutions [6] Group 7 - Domestic property stocks collectively declined, with Shimao Group (00813) falling nearly 5% and Zhongliang Holdings (02772) dropping over 3% [7]

消息面上，近日，据百奥赛图官微消息，公司与全球领先的科技公司默克(Merck)已签署一项抗体选择 权的评估协议，推进开发应用于核酸药物的抗体偶联脂质递送解决方案，例如抗体偶联脂质纳米颗粒 (LNP)。根据协议条款，百奥赛图将提供基于其RenMice平台自主开发的全人抗体，由默克评估将其用 于抗体偶联LNP制剂服务的可行性。默克被授予获取选中抗体资产权益的独家选择权，百奥赛图有权获 得相应的费用付款及销售分成和再许可分成。 据介绍，百奥赛图正在对1000多个潜在可成药的靶点进行规模化药物开发("千鼠万抗TM"计划)，并已 建立起超100万条全人抗体序列库，用于全球合作。截至2025年6月30日，百奥赛图已签署了约280项药 物合作开发/授权/转让协议，并与包括多家MNC在内的企业达成了50多个靶点项目RenMice平台授权开 发合作，多个临床阶段抗体分子也达成了对外授权合作。 （原标题：港股异动 | 百奥赛图-B(02315)涨超10% 与默克签署抗体选择权评估协议 推进抗体偶联脂质 递送解决方案） 智通财经APP获悉，百奥赛图-B(02315)涨超10%，截至发稿，涨10.43%，报25.4港元，成交额108 ...

Core Viewpoint - The stock of Baiaosaitu-B (02315) has increased by over 10%, currently trading at 25.4 HKD, following the announcement of a collaboration with Merck to develop antibody-conjugated lipid delivery solutions for nucleic acid drugs [1] Group 1: Partnership and Agreements - Baiaosaitu has signed an evaluation agreement with Merck to advance the development of antibody-conjugated lipid nanoparticle (LNP) solutions [1] - Under the agreement, Baiaosaitu will provide fully human antibodies developed on its RenMice platform for Merck to assess their feasibility for LNP formulation services [1] - Merck has been granted exclusive rights to acquire selected antibody assets, while Baiaosaitu will receive corresponding fee payments, sales shares, and sublicensing shares [1] Group 2: Development Pipeline - Baiaosaitu is conducting large-scale drug development targeting over 1,000 potential druggable targets under its "Thousand Mice, Ten Thousand Antibodies" program [1] - The company has established a library of over 1 million fully human antibody sequences for global collaborations [1] - As of June 30, 2025, Baiaosaitu has signed approximately 280 drug collaboration/development/transfer agreements and has engaged in over 50 target projects for RenMice platform development with various multinational corporations [1]

消息面上，近日，据百奥赛图官微消息，公司与全球领先的科技公司默克(Merck)已签署一项抗体选择 权的评估协议，推进开发应用于核酸药物的抗体偶联脂质递送解决方案，例如抗体偶联脂质纳米颗粒 (LNP)。根据协议条款，百奥赛图将提供基于其RenMice平台自主开发的全人抗体，由默克评估将其用 于抗体偶联LNP制剂服务的可行性。默克被授予获取选中抗体资产权益的独家选择权，百奥赛图有权获 得相应的费用付款及销售分成和再许可分成。 据介绍，百奥赛图正在对1000多个潜在可成药的靶点进行规模化药物开发("千鼠万抗TM"计划)，并已 建立起超100万条全人抗体序列库，用于全球合作。截至2025年6月30日，百奥赛图已签署了约280项药 物合作开发/授权/转让协议，并与包括多家MNC在内的企业达成了50多个靶点项目RenMice平台授权开 发合作，多个临床阶段抗体分子也达成了对外授权合作。 智通财经APP获悉，百奥赛图-B(02315)涨超10%，截至发稿，涨10.43%，报25.4港元，成交额1088.22万 港元。 ...